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Noninvasive Cardiac Radiation for Ablation
of Ventricular Tachycardia
Phillip S. Cuculich, M.D., Matthew R. Schill, M.D., Rojano Kashani, Ph.D.,
Sasa Mutic, Ph.D., Adam Lang, M.D., Daniel Cooper, M.D.,
Mitchell Faddis, M.D., Ph.D., Marye Gleva, M.D., Amit Noheria, M.B., B.S.,
Timothy W. Smith, M.D., D.Phil., Dennis Hallahan, M.D., Yoram Rudy, Ph.D.,
and Clifford G. Robinson, M.D.

A BS T R AC T
BACKGROUND

Recent advances have enabled noninvasive mapping of cardiac arrhythmias with
electrocardiographic imaging and noninvasive delivery of precise ablative radiation
with stereotactic body radiation therapy (SBRT). We combined these techniques to
perform catheter-free, electrophysiology-guided, noninvasive cardiac radioablation
for ventricular tachycardia.
METHODS

We targeted arrhythmogenic scar regions by combining anatomical imaging with
noninvasive electrocardiographic imaging during ventricular tachycardia that was
induced by means of an implantable cardioverter–defibrillator (ICD). SBRT simulation, planning, and treatments were performed with the use of standard techniques. Patients were treated with a single fraction of 25 Gy while awake. Efficacy
was assessed by counting episodes of ventricular tachycardia, as recorded by ICDs.
Safety was assessed by means of serial cardiac and thoracic imaging.
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RESULTS

From April through November 2015, five patients with high-risk, refractory ventricular
tachycardia underwent treatment. The mean noninvasive ablation time was 14 minutes (range, 11 to 18). During the 3 months before treatment, the patients had a
combined history of 6577 episodes of ventricular tachycardia. During a 6-week postablation “blanking period” (when arrhythmias may occur owing to postablation inflammation), there were 680 episodes of ventricular tachycardia. After the 6-week
blanking period, there were 4 episodes of ventricular tachycardia over the next 46
patient-months, for a reduction from baseline of 99.9%. A reduction in episodes of
ventricular tachycardia occurred in all five patients. The mean left ventricular ejection
fraction did not decrease with treatment. At 3 months, adjacent lung showed opacities consistent with mild inflammatory changes, which had resolved by 1 year.
CONCLUSIONS

In five patients with refractory ventricular tachycardia, noninvasive treatment with
electrophysiology-guided cardiac radioablation markedly reduced the burden of ventricular tachycardia. (Funded by Barnes–Jewish Hospital Foundation and others.)
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n clinical electrophysiology, non
invasive cardiac imaging methods, such as
cardiac magnetic resonance imaging (MRI)
and computed tomography (CT), help to identify
and localize myocardial scar that may have an
abnormal electrical substrate causing ventricular
tachycardia.1,2 The use of multielectrode bodysurface electrocardiography to create a cardiac
image (electrocardiographic imaging)3 in combination with standard cardiac imaging can identify in a noninvasive manner both myocardial
scar and the arrhythmogenic region from which
ventricular arrhythmias arise.3-6 With the use of
this technique, it is theoretically possible to develop a totally noninvasive method for ablation
of ventricular tachycardia if the imaging is combined with similarly noninvasive ablative techniques.
One such technique is stereotactic body radiation therapy (SBRT), which delivers precise,
high-dose radiation to targets in the body with
minimal damage to normal adjacent tissue.7
SBRT is most commonly used to treat tumors,
with high rates of tumor control and low rates of
toxic effects. Preclinical studies that have explored
SBRT for the ablation of cardiac arrhythmia
have identified doses that recapitulate the effects
of catheter radiofrequency ablation with 25 to
35 Gy delivered in a single fraction. This therapy has resulted in late myocardial fibrosis and
electrically inert tissue without evidence of acute
or subacute injury to nearby tissues during
6 months of follow-up.8,9 Clinical case reports have
shown the feasibility of the use of SBRT for this
purpose.10,11
Although catheter ablation is the current
state-of-the-art treatment for drug-refractory ventricular arrhythmias in patients with structural
heart disease,12 it is not curative for many patients.13-22 Common reasons for catheter-ablation
failures include inaccessible arrhythmogenic tissue and an inability to deliver adequate ablative
energy transmurally across ventricular myocardium. In addition, catheter ablation of ventricular tachycardia is associated with high risks of
procedural complication and death.23 SBRT has
the potential to overcome these challenges.8,9 In
this case series, we combined noninvasive mapping (electrocardiographic imaging) and noninvasive ablation (SBRT) to treat patients with refractory ventricular tachycardia.
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Me thods
Treatment Plan and Study Oversight

The treatment described in this article was delivered to patients on the basis of their clinical
circumstances, without specific testing of a research hypothesis. The treatment plan was designed by the first and last authors. All the authors participated in data collection and analysis
and in the writing of the manuscript. (Details
regarding the authors’ contributions are provided in the Supplementary Appendix, available with
the full text of this article at NEJM.org.) The
study received no industry support.
All the patients received a detailed explanation of the risks of treatment from both the treating electrophysiologist (the first author) and radiation oncologist (the last author); all the patients
provided written informed consent to treatment.
Institutional review board approval had previously been provided for the use of electrocardiographic imaging. At the time of the study, the
SBRT device had received 510(k) premarket approval from the Food and Drug Administration,
but its use in the patients reported here was
considered to be off-label clinical use; this information was conveyed to the patients who were
included in this study.
Study Patients

We evaluated patients with structural heart disease, placement of an implantable cardioverter–
defibrillator (ICD), and treatment-refractory ventricular tachycardia with limited conventional
therapeutic options for noninvasive cardiac ablation of ventricular tachycardia (noninvasive radio
ablation) on a case-by-case basis. Patients were
considered for noninvasive radioablation if they
had had at least three episodes of ICD-treated
ventricular tachycardia in the preceding 3 months,
despite having received at least two antiarrhythmic medications and having undergone at least
one catheter-ablation procedure (or having a contraindication to catheter ablation). Evaluation of
the patients for cardiac transplantation was encouraged, according to institutional standard of
care, but transplantation eligibility was not an
absolute condition for consideration. Patients who
had undergone placement of a left ventricular assist device were not evaluated for inclusion in the
study.
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Procedural Workflow

The procedural workflow for noninvasive radio
ablation is shown in Figure 1, with full details
provided in the Supplementary Appendix. Before
treatment, patients underwent noninvasive electrocardiographic imaging during induced ventricular tachycardia to precisely map the ventricular tachycardia circuit. For electrocardiographic
imaging, patients wore a vest of 256 electrodes
(BioSemi) and underwent chest CT scanning.
Patients were then brought to the electrophysiology laboratory and underwent noninvasive programmed stimulation with the use of an indwelling ICD to induce ventricular tachycardia.
Data for electrocardiographic imaging maps were
obtained, and the ICD was used to terminate
ventricular tachycardia with a brief overdrivepacing maneuver. Electrocardiographic imaging
maps were created to identify the site of earliest
electrical activation during ventricular tachycardia (the “exit site”), as described previously.3-6
When clinically available, additional cardiac
imaging was used to identify regions of anatomical scarring with either resting single-photon emission CT (SPECT) or contrast-enhanced
cardiac MRI with the use of standard techniques
(Fig. 1). Electrical information from the electrocardiographic imaging and information from
the anatomical scarring were combined to build
a volumetric target for radioablation that targeted the area of the first 10 msec of ventricular
tachycardia (the exit site) and the full myocardial thickness of the associated ventricular scar.
In addition, before treatment, patients underwent a planning CT scan, which included immobilization of the entire body from thorax to legs
with the use of a vacuum-assisted device (BodyFIX, Elekta) and acquisition of a respiration-correlated CT scan (four-dimensional CT) to assess
the sum total of cardiac and pulmonary motion.
A final target (planning target volume) was
developed by expanding the target, as defined
above, to account for motion, setup uncertainty, and delivery uncertainty. (Details about this
method are provided in the Supplementary Appendix.)
A total dose of 25 Gy in a single fraction was
prescribed to be administered to the planning
target volume with a goal of achieving maximal
dose coverage while avoiding a dose in excess of
calculated dose constraints to surrounding organs,
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including the esophagus, stomach, lungs, and
spinal cord. All plans were subjected to, and
passed, standard internal physics quality assurance
on a calibrated phantom before delivery.
SBRT was performed with the use of an image-guided radiotherapy-equipped linear accelerator (TrueBeam, Varian Medical Systems) that
uses cone-beam CT to acquire images of the thorax, which can be directly registered to the planning CT. This procedure results in accurate alignment of the heart and target volume without the
need for invasive placement of a fiducial marker.
During treatment, patients were placed in their
custom immobilization device, which was aligned
with the use of the cone-beam CT, with verification of the alignment by means of fluoroscopy.
All the patients were treated without the use of
any additional imaging during treatment and
without sedation or anesthesia.
Outcome Assessments

After treatment, patients were followed according to our standard of care for patients undergoing ablation of ventricular tachycardia. All ICDs
were reprogrammed with a monitor-only zone at
100 bpm to assess for slow ventricular tachycardia. Patients were enrolled in a remote monitoring program for devices to enhance rapid identification and interpretation of any ICD-detected
arrhythmias. Patients were seen in the outpatient
clinic with ICD interrogations every 2 weeks for
2 months, monthly for the next 4 months, and
then 1 year after treatment.
At each visit, an attempt was made to wean
patients off their antiarrhythmic medications to
mitigate known short-term and long-term toxic
effects of these drugs. If no further ventricular
arrhythmias were detected, doses of antiarrhythmic medications were reduced or stopped, with
the goal of discontinuing all antiarrhythmic
medications after the 6-week visit. Patients continued to receive medical therapy (including beta-blockers) for heart failure before and after
treatment.
We tallied episodes of ventricular tachycardia
as the sum of appropriate ICD shocks, appropriate ICD antitachycardia pacing, and sustained
(>30 seconds), nontreated ventricular tachycardia
in the monitor zone. The treating electrophysiologists adjudicated all ICD interrogations. Patients underwent echocardiography at baseline

nejm.org

December 14, 2017

2327

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on January 9, 2018. For personal use only. No other uses without permission.
Copyright © 2017 Massachusetts Medical Society. All rights reserved.

The

Visualize Anatomical Scar

n e w e ng l a n d j o u r na l

Isochrones

or
SPECT

and

190
180
170
160
150
140
130
120
110
100
90
80
70
60
50
40
30
20
10

m e dic i n e

Identify Arrhythmogenic
Scar Substrate

Perform EP Mapping

MRI

of

ECGI map

Create a contoured
target volume

AORTA

LEFT
A T R IU M

R I GH T
V E NT RIC L E

LAD
ARTERY

LEFT
V E NT R I C L E

Epicardial
VT exit site

Position

Develop Plan

Image and Align

2328

Treat

n engl j med 377;24

nejm.org

December 14, 2017

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on January 9, 2018. For personal use only. No other uses without permission.
Copyright © 2017 Massachusetts Medical Society. All rights reserved.

R adiation for Ablation of Ventricular Tachycardia

Figure 1 (facing page). Workflow for ElectrophysiologyGuided, Noninvasive Cardiac Radioablation.
Patients undergo noninvasive visualization of the ventricular scar by means of MRI, CT, single-photon emission CT (SPECT), or a combination of methods, according to clinical routine. The zone of scarring is
indicated by arrows on MRI and by blue regions on
SPECT, including the base, inferior wall, and apex.
Noninvasive electrophysiologic (EP) mapping is performed with electrocardiographic imaging (ECGI) of
induced ventricular tachycardia (VT) with programed
stimulation from the indwelling implantable cardioverter–defibrillator. The color scale shows the range of
activation times of each area of the ventricular wall
(isochrones), ranging from 10 msec (red) to 190 msec
(deep blue) from the onset of VT activation. The electrophysiologist develops an ablation volume by targeting the full thickness of the ventricular wall harboring
the first 10 msec of VT activation (the “exit site”) and
the colocalized ventricular scar. (Details regarding
scar imaging, EP mapping, and image fusion to develop the ablation volume are provided in the Supplementary Appendix.) The target volume is shown in
light blue in the figure panel showing the arrhythmogenic scar substrate. This volume is transferred by the
radiation oncologist onto a respiratory-correlated,
four-dimensional CT scan, which allows an assessment of the total cardiac and pulmonary motion. In
this example, a dose of 25 Gy in a single fraction is
prescribed for delivery to the enhanced treatment volume, with a goal of achieving maximal coverage inside
the volume while avoiding exposure to the surrounding organs at risk. The target volume is indicated in
light blue in the figure panel showing the treatment
plan; red and yellow boundaries indicate the distribution of zones projected to receive 2750 cGy and 2375
cGy of radiation, respectively; the lung is outlined in
orange, and the yellow boundary behind the heart is
the esophagus. If all plans pass standard internal
physics quality assurance on a calibrated phantom,
the patient is immobilized with the use of a vacuumassisted device, and stereotactic radioablation is performed by means of an image-guided, radiotherapyequipped linear accelerator that uses a cone-beam CT
to align the radiotherapy treatment beams with the
target volume. The dark blue boundary indicates the
target, which includes the total cardiac and pulmonary
motion. The light blue boundary indicates the target
with an additional expansion to account for motion,
setup uncertainty, and delivery uncertainty. Treatment
is then delivered with the use of the radiotherapy delivery system. LAD denotes left anterior descending.

and at 1, 6, and 12 months after treatment to
assess for cardiac adverse events. Patients also
underwent chest CT at baseline and at 3 and 12
months to assess for thoracic adverse events in

n engl j med 377;24

accordance with routine standard of care for
thoracic SBRT.

R e sult s
Patients

From April through November 2015, nine patients were evaluated for noninvasive radioablation; of these patients, five received the treatment.
Of the four patients who did not receive treatment, two declined to participate (one chose to
enter hospice care and died from complications
of ventricular tachycardia 1 week later, and one
chose to undergo an invasive procedure for ventricular tachycardia ablation), one died of progressive cardiogenic shock before treatment, and
one underwent implantation of a left ventricular
assist device, with recurrent ventricular tachycardia storm after surgery.
Table 1 outlines the demographic and clinical
data for each patient; further clinical details are
provided in the Supplementary Appendix. The
mean age of the five treated patients was 66 years
(range, 60 to 83). The mean number of episodes
of ventricular tachycardia per patient in the 3
months before treatment was 1315 (range, 5 to
4312). All the patients were taking two antiarrhythmic drugs at the time of evaluation. Previous invasive catheter-ablation procedures had
failed in three patients. Two patients had contraindications to invasive catheter ablation: one (Patient 2) had a new mechanical prosthetic mitral
valve and evidence of epicardial ventricular tachycardia, and one (Patient 5) was deemed to be too
frail for any invasive procedures. All five patients
had New York Heart Association class III or IV
heart-failure symptoms. The mean left ventricular
ejection fraction was 23% (range, 15 to 37).
Noninvasive Radioablation Procedure

Procedural details for each patient are provided
in the Supplementary Appendix. All the patients
underwent noninvasive electrocardiographic imaging for mapping of their ventricular tachycardia. Four patients had inducible ventricular tachycardia (mean number of circuits, three; range, one
to six). Electrocardiographic imaging was performed during all induced episodes of ventricular
tachycardia. In one patient (Patient 3), ventricular
tachycardia could not be induced and no electrocardiographic imaging was obtainable, so the re-
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sults of 12-lead electrocardiography and previous invasive catheter mapping were used to guide
the creation of a volumetric target.
Treatment characteristics are provided in Table 1. Ablation target volumes ranged from 17 to
81 ml (mean, 49). On-table treatment times ranged
from 11 to 18 minutes (mean, 14).
Ventricular Tachycardia Burden

change in the left ventricular ejection fraction at
the last follow-up visit was an absolute increase
of 6 percentage points (range, −2 to 22) (Fig. 3A).
No pulmonary symptoms occurred after treatment. Serial CT at 3 months showed findings
that were consistent with inflammatory changes
in the adjacent lung tissue that were typical of
thoracic SBRT, with near-complete resolution at
12 months (Fig. 3B). At 12 months, there was no
chest pain or apparent changes to the myocardium or coronary arteries on CT in the region
targeted for treatment.
During follow-up, after amiodarone was discontinued, sinus-node function recovered in three
patients. Heart rates in sinus rhythm occasionally exceeded the ICD programmed cutoff rate for
detection (100 bpm). This situation required ICD
reprogramming to avoid inappropriate therapy.
One patient (Patient 5) had a fatal stroke 3
weeks after treatment. This 83-year-old woman
had a history of atrial fibrillation, severe cardiomyopathy, and other risk factors for stroke. Because of a risk of frailty-related bleeding, oral
anticoagulants were not prescribed for stroke
prevention. In the 3 weeks after treatment, her
burden of ventricular tachycardia was reduced by
82% (from 1777 episodes of antitachycardia pacing in the month before treatment to 322 episodes after treatment). Her left ventricular ejection fraction had increased from 15% to 30%.
No intracardiac thrombus was seen on echocardiography or during pathological assessment. It
remains unclear whether the stroke was associated with SBRT or with preexisting medical conditions that placed her at high risk for stroke.
(Additional information about this patient is provided in the following section.)

At a median follow-up of 12 months, a marked
reduction in the burden of ventricular tachycardia occurred after treatment (Table 1 and Fig. 2).
In aggregate, there were 6577 episodes of ventricular tachycardia in the 15 patient-months
before treatment. During the 6 weeks immediately after ablation (the “blanking period,” when
arrhythmias may occur because of postablation
inflammation), there were 680 episodes of ventricular tachycardia. After the 6-week blanking
period, there were 4 episodes of ventricular tachycardia during the next 46 patient-months, for a
relative reduction of 99.9% from baseline.
Figure 2A shows the monthly number of episodes of ventricular tachycardia on a per-patient
basis. Every patient had a reduction in ventricular tachycardia burden. Of the four patients who
were alive at 12 months, three were not receiving
any antiarrhythmic medication. Patient 3 restarted amiodarone 9 months after treatment after the
first episode of antitachycardia pacing. Patient 4
underwent an additional invasive catheter ablation procedure at 4 weeks after treatment because of incomplete cessation of ventricular
tachycardia, with no further episodes thereafter.
Improvement was observed with respect to both
the number of ICD shocks (an aggregate number
of 55 ICD shocks before treatment vs. 1 shock
after treatment) (Fig. 2B) and ICD antitachycardia pacing (6577 episodes before treatment vs. 3 Cardiac Radiobiologic Effect
episodes after treatment) (Fig. 2C).
Consent was obtained for postmortem cardiac
pathological assessment in Patient 5. Prominent
Adverse Events
ectatic blood vessels were identified at the interNo complications occurred during the treatment face of dense scar and viable myocardium (scar
or index hospitalization. Three patients reported border zone) (Fig. 4A). This pattern has been
fatigue on the day after treatment. No acute heart- described as a component of the acute vascular
failure exacerbations occurred in the immediate injury that is usually observed in the early weeks
period after treatment. Patients were discharged after radiation exposure. In such cases, the inhome 1 to 3 days after treatment.
jury pattern is typically accompanied by endoNo adverse effects were observed in ICD system thelial-cell swelling, vacuolization, and perivasperformance, lead thresholds, or lead impedances cular tissue edema.24 However, in this patient,
at any point after treatment. Serial echocardiog- the endothelial lining of these vessels appeared
raphy showed no pericardial effusions. The mean to be normal and nonreactive, without evidence
n engl j med 377;24
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Figure 2 (facing page). Assessment of Treatment
Efficacy.
Panel A shows the total number of episodes of ventricular tachycardia (VT), including appropriate shocks
from an implantable cardioverter–defibrillator (ICD),
appropriate ICD antitachycardia pacing, and sustained
untreated VT, in each of the five study patients, for
3 consecutive months before treatment and continuing for 12 months after treatment. In Patients 4 and 5,
the numbers of VT episodes were markedly greater
than in Patients 1, 2, and 3; therefore, the numbers
that are shown for Patients 4 and 5 have been divided
by 30 to allow comparisons on the same scale. Also
shown are the total numbers of ICD shocks (Panel B)
and numbers of episodes of antitachycardia pacing
(Panel C) for all five patients during the same time
frame. Six weeks after treatment, all four surviving patients were able to discontinue their antiarrhythmic
medications, although Patient 3 restarted amiodarone
9 months after treatment of the first episode of antitachycardia pacing. Four weeks after treatment, Patient
4 underwent invasive catheter ablation because of incomplete cessation of ventricular tachycardia, with no
further episodes by 12 months.

of an acute vasculitis or tissue edema (Fig. 4B).
We observed no evidence of acute myocyte necrosis, hemorrhage, or acute inflammation. The
relative contributions of remote myocardial infarction and acute cardiac SBRT to the formation
of dense scar are unknown.

Discussion
In this case series involving five patients with
treatment-refractory ventricular tachycardia, a
marked reduction in the burden of ventricular
tachycardia was achieved with a noninvasive method for mapping and treating the arrhythmogenic
area of the heart. The patients were selected for
this treatment because they had end-stage disease, with a low likelihood of survival free from
further episodes of ventricular tachycardia. The
average treatment time was under 15 minutes.
Most of the patients were able to stop antiarrhythmic medications several weeks after treatment,
and the antiarrhythmic effect continued throughout the first year.
Worldwide, invasive catheter ablation is increasingly performed to treat ventricular tachycardia.12 The procedure is largely effective in the

n engl j med 377;24

absence of ventricular scar (idiopathic ventricular tachycardia). However, catheter ablation for
cardiomyopathic ventricular tachycardia is associated with recurrence rates as high as 50% at
6 months.13-22 Patients with recurrence of ventricular tachycardia despite catheter ablation have a
poor prognosis associated with progressive heart
failure and irrepressible ventricular tachycardia,
with a risk of death that is four to six times the
risk among patients who do not have such a recurrence.13,15,17,25
Recurrences of ventricular tachycardia occur
for several reasons, including the presence of
multiple coexisting ventricular tachycardia circuits, the presence of circuits that extend deep
within the myocardium outside the reach of
standard catheter-ablation energy, and the formation of new circuits after the ablation procedure. Success rates are higher with more extensive ablation, including the use of combined
endocardial and epicardial approaches in an effort to “homogenize” the scar.26-28 For patients
with ventricular tachycardia that cannot be treated effectively with standard catheter ablation,
investigators are developing and testing invasive
alternative treatments with higher procedural
risks, including surgical access to the epicardial
space for catheter ablation, surgical sympathetic
denervation, transcoronary ethanol injection, and
catheter ablation with an extendable needle.29
Thus, if a noninvasive approach to ablation of
ventricular tachycardia is shown to be safe and
effective, it would be a potentially important therapeutic advance.
Because of the novelty of noninvasive radioablation, its potential for harm, and the limited
number of patients who were included in this
analysis, this procedure should not be considered to be suitable for clinical use, pending the
results of further research studies. Furthermore,
there are well-described late toxic effects of radiotherapy to the heart for large-field fractionateddose treatments, as has been reported in the
treatment of lymphoma and breast cancer.25,30
The potential late effects of high-dose SBRT exclusively to focal areas of previously injured
heart are unknown. The volumes of myocardium
that are subjected to radiotherapy in these patients (from 17 to 81 ml) are large enough that
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Figure 3. Assessment of Adverse Effects.
Panel A shows serial evaluation of the left ventricular ejection fraction after treatment in each of the study patients,
as assessed on echocardiography. The mean value increased by 6 percentage points (range, −2 to 22). Panel B
shows serial thoracic CT scans after treatment in Patient 1. The treatment area is shown in blue. At 3 months, there
were adjacent local inflammatory changes in the lung parenchyma, effects that had nearly resolved at 12 months.
A similar pattern was observed in the other study patients.

effects on specialized cardiac structures (papillary muscles, coronary arteries, conduction system, and valves) are of potential concern, as is the
risk of overall effects on ventricular function, although no such effects were seen during the
12-month follow-up period in the four surviving
patients in our study. The risk of thromboembo-
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lism, as observed in Patient 5, warrants cautious
consideration. We have initiated a prospective
phase 1–2 trial (ENCORE-VT) to evaluate the safety
and efficacy of SBRT (ClinicalTrials.gov number,
NCT02919618).
In conclusion, in five patients with intractable ventricular tachycardia, the use of nonin-
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A

Figure 4. Histologic Assessment of Targeted
Myocardium on Autopsy.
Panel A shows prominent small-vessel ectasis at the
interface of dense fibrosis (upper right) and viable
myocardium (lower left) in postmortem cardiac samples obtained from Patient 5, who had a fatal stroke
3 weeks after treatment. There is no acute myocardial
inflammation or acute cellular necrosis. Panel B from
the transition region shows occasional rectangular
“boxcar” nuclei (white arrow) and hypertrophic cardiomyocytes, which are observed in chronic stages of
heart failure. Endothelial cells are normal in appearance (black arrows), showing long, thin, nonreactive
nuclei. (Hematoxylin and eosin staining was used in
both panels.)

B

vasive stereotactic cardiac radiotherapy as an
ablation technique resulted in a marked reduction in the burden of ventricular tachycardia after treatment.
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